{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:30:46Z","timestamp":1792557046997,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":388,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jacc.2025.03.544","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T10:04:06Z","timestamp":1750068246000},"page":"2401-2415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Heart Failure With Improved Ejection Fraction"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3444-1916","authenticated-orcid":false,"given":"Mauro","family":"Riccardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1883-0654","authenticated-orcid":false,"given":"Maria A.","family":"Pabon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6449-4535","authenticated-orcid":false,"given":"Ankeet S.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7732-0887","authenticated-orcid":false,"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6691-8568","authenticated-orcid":false,"given":"Marco","family":"Metra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Volterrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7120-5877","authenticated-orcid":false,"given":"Carlo M.","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Vardeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4846-8529","authenticated-orcid":false,"given":"Riccardo M.","family":"Inciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jacc.2025.03.544_bib1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.jacc.2025.03.544_bib2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"Authors\/Task Force Members","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"10.1016\/j.jacc.2025.03.544_bib3","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacc.2025.03.544_bib4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jacc.2020.05.075","article-title":"Heart failure with recovered left ventricular ejection fraction: JACC scientific expert panel","volume":"76","author":"Wilcox","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jacc.2025.03.544_bib5","first-page":"924","article-title":"[Heart failure with improved ejection fraction: practical guidance for the clinician]","volume":"23","author":"Gori","year":"2022","journal-title":"G Ital Cardiol (Rome)"},{"issue":"23","key":"10.1016\/j.jacc.2025.03.544_bib6","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1161\/CIRCULATIONAHA.113.006855","article-title":"Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes","volume":"129","author":"Basuray","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacc.2025.03.544_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002826","article-title":"Heart failure and midrange ejection fraction: implications of recovered ejection fraction for exercise tolerance and outcomes","volume":"9","author":"Nadruz","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"3","key":"10.1016\/j.jacc.2025.03.544_bib8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000447287","article-title":"Heart failure with recovered ejection fraction in a cohort of elderly patients with chronic heart failure","volume":"135","author":"Trull\u00e0s","year":"2016","journal-title":"Cardiology"},{"issue":"5","key":"10.1016\/j.jacc.2025.03.544_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cardfail.2017.09.005","article-title":"Heart failure with recovered ejection fraction in African Americans: results from the African-American Heart Failure Trial","volume":"24","author":"Chang","year":"2018","journal-title":"J Card Fail"},{"issue":"3","key":"10.1016\/j.jacc.2025.03.544_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.5603\/CJ.a2017.0103","article-title":"Heart failure with recovered ejection fraction: Clinical characteristics, determinants and prognosis. CARDIOCHUS-CHOP registry","volume":"25","author":"Agra","year":"2018","journal-title":"Cardiol J"},{"issue":"5","key":"10.1016\/j.jacc.2025.03.544_bib11","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/jamacardio.2016.1325","article-title":"Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction","volume":"1","author":"Kalogeropoulos","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.544_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.medcli.2018.05.001","article-title":"Long-term and clinical profile of heart failure with recovered ejection fraction in a non-tertiary hospital","volume":"152","author":"Mart\u00ednez-Mateo","year":"2019","journal-title":"Med Clin (Barc)"},{"issue":"12","key":"10.1016\/j.jacc.2025.03.544_bib13","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/ejhf.824","article-title":"Recovered heart failure with reduced ejection fraction and outcomes: a prospective study","volume":"19","author":"Lup\u00f3n","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.544_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.757596","article-title":"Prevalence and prognosis of HFimpEF developed from patients with heart failure with reduced ejection fraction: systematic review and meta-analysis","volume":"8","author":"He","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"10.1016\/j.jacc.2025.03.544_bib15","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1002\/ejhf.3031","article-title":"Heart failure patients with improved ejection fraction: Insights from the MECKI score database","volume":"25","author":"Agostoni","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.jacc.2025.03.544_bib16","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003123","article-title":"Heart failure with improved ejection fraction: clinical characteristics, correlates of recovery, and survival: results from the Valsartan Heart Failure Trial","volume":"9","author":"Florea","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.544_bib17","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1253\/circj.CJ-12-0507","article-title":"Predictors of left ventricular reverse remodeling and subsequent outcome in nonischemic dilated cardiomyopathy","volume":"77","author":"Choi","year":"2013","journal-title":"Circ J"},{"issue":"26","key":"10.1016\/j.jacc.2025.03.544_bib18","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1093\/eurheartj\/ehz233","article-title":"Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study","volume":"40","author":"Ghimire","year":"2019","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.jacc.2025.03.544_bib19","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/ejhf.2512","article-title":"Transient versus persistent improved ejection fraction in non-ischaemic dilated cardiomyopathy","volume":"24","author":"Manca","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"13","key":"10.1016\/j.jacc.2025.03.544_bib20","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jacc.2010.11.030","article-title":"Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment","volume":"57","author":"Merlo","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.03.544_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.amjcard.2023.10.086","article-title":"Clinical, echocardiographic, and longitudinal characteristics associated with heart failure with improved ejection fraction","volume":"211","author":"Romero","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.03.544_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.770650","article-title":"A universal new definition of heart failure with improved ejection fraction for patients with coronary artery disease","volume":"12","author":"Huang","year":"2021","journal-title":"Front Physiol"},{"issue":"12","key":"10.1016\/j.jacc.2025.03.544_bib23","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1002\/ejhf.3378","article-title":"Heart failure with improved versus persistently reduced left ventricular ejection fraction: a comparison of the BIOSTAT-CHF (European) study with the ASIAN-HF registry","volume":"26","author":"Cao","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10.1016\/j.jacc.2025.03.544_bib24","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.cardfail.2023.06.022","article-title":"Heart failure with recovered ejection fraction in patients with nonischemic cardiomyopathy: characteristics, outcomes, and long-term follow-up","volume":"29","author":"Hammer","year":"2023","journal-title":"J Card Fail"},{"issue":"1","key":"10.1016\/j.jacc.2025.03.544_bib25","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ehf2.13133","article-title":"Late gadolinium enhancement for re-worsening left ventricular ejection fraction in patients with dilated cardiomyopathy","volume":"8","author":"Nabeta","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10.1016\/j.jacc.2025.03.544_bib26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00380-018-1214-5","article-title":"Dilated cardiomyopathy with re-worsening left ventricular ejection fraction","volume":"34","author":"Nabeta","year":"2019","journal-title":"Heart Vessels"},{"issue":"12","key":"10.1016\/j.jacc.2025.03.544_bib27","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1002\/ejhf.3410","article-title":"In-hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial","volume":"26","author":"Pabon","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.jacc.2025.03.544_bib28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jacc.2018.05.042","article-title":"Dynamic trajectories of left ventricular ejection fraction in heart failure","volume":"72","author":"Lup\u00f3n","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.03.544_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.amjcard.2023.06.047","article-title":"Risk of appropriate implantable cardioverter-defibrillator therapies and sudden cardiac death in patients with heart failure with improved left ventricular ejection fraction","volume":"213","author":"Al-Sadawi","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.03.544_bib30","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijcard.2022.03.046","article-title":"Clinical characteristics, predictors, and outcomes of heart failure with improved ejection fraction","volume":"357","author":"Su","year":"2022","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.jacc.2025.03.544_bib31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/jamacardio.2023.5318","article-title":"Dapagliflozin and mode of death in heart failure with improved ejection fraction: a post hoc analysis of the DELIVER trial","volume":"9","author":"Vardeny","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.jacc.2025.03.544_bib32","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1002\/ehf2.14098","article-title":"Quality of life in patients with heart failure and improved ejection fraction: one-year changes and prognosis","volume":"9","author":"Zamora","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.544_bib33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrcardio.2017.139","article-title":"Reverse remodelling and myocardial recovery in heart failure","volume":"15","author":"Kim","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"24","key":"10.1016\/j.jacc.2025.03.544_bib34","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.jacc.2012.06.062","article-title":"Myocardial recovery and the failing heart: myth, magic, or molecular target?","volume":"60","author":"Mann","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacc.2025.03.544_bib35","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001504","article-title":"Persistent recovery of normal left ventricular function and dimension in idiopathic dilated cardiomyopathy during long-term follow-up: does real healing exist?","volume":"4","author":"Merlo","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.jacc.2025.03.544_bib36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cardfail.2011.03.005","article-title":"Heart failure with recovered ejection fraction: a distinct clinical entity","volume":"17","author":"Punnoose","year":"2011","journal-title":"J Card Fail"},{"issue":"1","key":"10.1016\/j.jacc.2025.03.544_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ahj.2011.10.001","article-title":"Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF","volume":"163","author":"Wilcox","year":"2012","journal-title":"Am Heart J"},{"issue":"7","key":"10.1016\/j.jacc.2025.03.544_bib38","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006833","article-title":"Improvement in left ventricular ejection fraction in outpatients with heart failure with reduced ejection fraction: data from CHAMP-HF","volume":"13","author":"DeVore","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.544_bib39","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2020.13","article-title":"Heart failure with mid-range or recovered ejection fraction: differential determinants of transition","volume":"6","author":"Margonato","year":"2020","journal-title":"Card Fail Rev"},{"issue":"4","key":"10.1016\/j.jacc.2025.03.544_bib40","first-page":"333","article-title":"[Clinical characteristics of heart failure with recovered ejection fraction]","volume":"49","author":"Luo","year":"2021","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"5","key":"10.1016\/j.jacc.2025.03.544_bib41","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10554-016-1042-6","article-title":"Left ventricular reverse remodeling in dilated cardiomyopathy- maintained subclinical myocardial systolic and diastolic dysfunction","volume":"33","author":"Amorim","year":"2017","journal-title":"Int J Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.jacc.2025.03.544_bib42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.advms.2024.02.009","article-title":"Clinical characteristics and long-term outcomes of patients with heart failure with improved ejection fraction. First Polish experience from LECRA-HF registry","volume":"69","author":"St\u0119pie\u0144","year":"2024","journal-title":"Adv Med Sci"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.544_bib43","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1067\/mhj.2003.105","article-title":"Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance","volume":"145","author":"Metra","year":"2003","journal-title":"Am Heart J"},{"issue":"30","key":"10.1016\/j.jacc.2025.03.544_bib44","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1093\/eurheartj\/ehae334","article-title":"Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study","volume":"45","author":"Veltmann","year":"2024","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacc.2025.03.544_bib45","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jchf.2022.09.009","article-title":"Prediction of left ventricular ejection fraction change following treatment with sacubitril\/valsartan","volume":"11","author":"Mohebi","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.jacc.2025.03.544_bib46","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCIMAGING.112.000138","article-title":"Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium","volume":"6","author":"Ling","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.544_bib47","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/ehf2.15095","article-title":"Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy","volume":"12","author":"Colombo","year":"2025","journal-title":"ESC Heart Fail."},{"issue":"1","key":"10.1016\/j.jacc.2025.03.544_bib48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/HJR.0b013e3282f00990","article-title":"Left ventricular remodelling in patients with moderate systolic dysfunction after myocardial infarction: favourable effects of exercise training and predictive role of N -terminal pro-brain natriuretic peptide","volume":"15","author":"Giallauria","year":"2008","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"7","key":"10.1016\/j.jacc.2025.03.544_bib49","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/ejhf.3264","article-title":"Mechanisms of myocardial reverse remodelling and its clinical significance: a scientific statement of the ESC Working Group on Myocardial Function","volume":"26","author":"Falc\u00e3o-Pires","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.544_bib50","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3390\/nu12020572","article-title":"The effects of ethanol on the heart: alcoholic cardiomyopathy","volume":"12","author":"Fern\u00e1ndez-Sol\u00e0","year":"2020","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.jacc.2025.03.544_bib51","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41569-020-00435-x","article-title":"Myocarditis and inflammatory cardiomyopathy: current evidence and future directions","volume":"18","author":"Tsch\u00f6pe","year":"2021","journal-title":"Nat Rev Cardiol"},{"issue":"17","key":"10.1016\/j.jacc.2025.03.544_bib52","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.jacc.2021.08.039","article-title":"Association of genetic variants with outcomes in patients with nonischemic dilated cardiomyopathy","volume":"78","author":"Escobar-Lopez","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacc.2025.03.544_bib53","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1002\/ehf2.15009","article-title":"Genotype is associated with left ventricular reverse remodelling and early events in recent-onset dilated cardiomyopathy","volume":"11","author":"Kubanek","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"11","key":"10.1016\/j.jacc.2025.03.544_bib54","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005220","article-title":"Clinical phenotype and genotype associations with improvement in left ventricular function in dilated cardiomyopathy","volume":"11","author":"Verdonschot","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"17","key":"10.1016\/j.jacc.2025.03.544_bib55","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jacc.2017.02.049","article-title":"Histopathological and immunological characteristics of tachycardia-induced cardiomyopathy","volume":"69","author":"Mueller","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jacc.2025.03.544_bib56","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jacc.2020.10.060","article-title":"Pathophysiology of takotsubo syndrome: JACC state-of-the-art review","volume":"77","author":"Lyon","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacc.2025.03.544_bib57","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1253\/circj.CJ-18-0571","article-title":"Transcatheter repair of functional mitral regurgitation in heart failure patients\u2014a meta-analysis of 23 studies on MitraClip implantation","volume":"82","author":"De Rosa","year":"2018","journal-title":"Circ J"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.544_bib58","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jacc.2019.11.014","article-title":"Peripartum cardiomyopathy: JACC state-of-the-art review","volume":"75","author":"Davis","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.544_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2018-000850","article-title":"Morphofunctional cardiac changes in pregnant women: associations with biomarkers","volume":"5","author":"Umazume","year":"2018","journal-title":"Open Heart"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.544_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211982","article-title":"Factors associated with increased levels of brain natriuretic peptide and cardiac troponin I during the peripartum period","volume":"14","author":"Kimura","year":"2019","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jacc.2025.03.544_bib61","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.echo.2012.04.001","article-title":"Subclinical myocardial dysfunction in patients with reverse-remodeled dilated cardiomyopathy","volume":"25","author":"Okada","year":"2012","journal-title":"J Am Soc Echocardiogr"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.544_bib62","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4250\/jcvi.2019.0111","article-title":"Left ventricular global longitudinal strain as a predictor for left ventricular reverse remodeling in dilated cardiomyopathy","volume":"28","author":"Jung","year":"2020","journal-title":"J Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.jacc.2025.03.544_bib63","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003788","article-title":"Abnormal global longitudinal strain predicts future deterioration of left ventricular function in heart failure patients with a recovered left ventricular ejection fraction","volume":"10","author":"Adamo","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"20","key":"10.1016\/j.jacc.2025.03.544_bib64","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009841","article-title":"Baseline longitudinal strain predicts recovery of left ventricular ejection fraction in hospitalized patients with nonischemic cardiomyopathy","volume":"7","author":"Swat","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jacc.2025.03.544_bib65","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jchf.2021.08.007","article-title":"Prognostic value of global longitudinal strain in patients with heart failure with improved ejection fraction","volume":"10","author":"Janwanishstaporn","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.544_bib66","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026891","article-title":"Reverse atrial remodeling in heart failure with recovered ejection fraction","volume":"12","author":"Sun","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.jacc.2025.03.544_bib67","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.echo.2021.03.016","article-title":"Left atrial strain associated with functional recovery in patients receiving optimal treatment for heart failure","volume":"34","author":"Torii","year":"2021","journal-title":"J Am Soc Echocardiogr"},{"issue":"9","key":"10.1016\/j.jacc.2025.03.544_bib68","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jcmg.2022.03.019","article-title":"Reverse remodeling assessed by left atrial and ventricular strain reflects treatment response to sacubitril\/valsartan","volume":"15","author":"Moon","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"issue":"11","key":"10.1016\/j.jacc.2025.03.544_bib69","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1161\/01.CIR.0000120294.67948.E3","article-title":"Role of cardiac magnetic resonance imaging in the assessment of myocardial viability","volume":"109","author":"Shan","year":"2004","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jacc.2025.03.544_bib70","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00380-022-02057-4","article-title":"Native T1 heterogeneity for predicting reverse remodeling in patients with non-ischemic dilated cardiomyopathy","volume":"37","author":"Kinoshita","year":"2022","journal-title":"Heart Vessels"},{"issue":"9","key":"10.1016\/j.jacc.2025.03.544_bib71","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.amjcard.2017.01.023","article-title":"Relation of myocardial contrast-enhanced T1 mapping by cardiac magnetic resonance to left ventricular reverse remodeling after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy","volume":"119","author":"H\u00f6ke","year":"2017","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.jacc.2025.03.544_bib72","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/eurjhf\/hfs180","article-title":"Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study","volume":"15","author":"Weiner","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.544_bib73","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jchf.2018.10.014","article-title":"NT-proBNP goal achievement is associated with significant reverse remodeling and improved clinical outcomes in HFrEF","volume":"7","author":"Daubert","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"16","key":"10.1016\/j.jacc.2025.03.544_bib74","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jacc.2022.08.737","article-title":"Dose-response to sacubitril\/valsartan in patients with heart failure and reduced ejection fraction","volume":"80","author":"Mohebi","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacc.2025.03.544_bib75","first-page":"468","article-title":"Soluble ST2 in heart failure: a clinical role beyond B-type natriuretic peptide","volume":"10","author":"Riccardi","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"issue":"1","key":"10.1016\/j.jacc.2025.03.544_bib76","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jchf.2013.10.005","article-title":"Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure","volume":"2","author":"Gaggin","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.544_bib77","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijcard.2015.02.019","article-title":"Biomarker-assist score for reverse remodeling prediction in heart failure: the ST2-R2 score","volume":"184","author":"Lup\u00f3n","year":"2015","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.jacc.2025.03.544_bib78","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1161\/01.CIR.103.3.369","article-title":"Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes","volume":"103","author":"Sato","year":"2001","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacc.2025.03.544_bib79","doi-asserted-by":"crossref","first-page":"42","DOI":"10.14797\/mdcvj.1381","article-title":"Role of imaging and biomarkers in identifying, monitoring, and promoting myocardial recovery","volume":"20","author":"Meekers","year":"2024","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"10","key":"10.1016\/j.jacc.2025.03.544_bib80","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1002\/ejhf.3397","article-title":"Biomarker profiles associated with reverse ventricular remodelling in patients with heart failure and a reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trial","volume":"26","author":"Tromp","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.jacc.2025.03.544_bib81","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1161\/01.CIR.91.10.2573","article-title":"Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy","volume":"91","author":"Greenberg","year":"1995","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacc.2025.03.544_bib82","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/j.jacc.2003.12.053","article-title":"Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan Heart Failure Trial (Val-HeFT) echocardiographic data","volume":"43","author":"Wong","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jacc.2025.03.544_bib83","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.amjcard.2010.06.052","article-title":"Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure","volume":"106","author":"Vizzardi","year":"2010","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.jacc.2025.03.544_bib84","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCHEARTFAILURE.109.906909","article-title":"Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction","volume":"3","author":"Udelson","year":"2010","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.544_bib85","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5455\/medarh.2023.77.105-111","article-title":"The effectiveness of eplerenone vs spironolactone on left ventricular systolic function, hospitalization and cardiovascular death in patients with chronic heart failure-HFrEF","volume":"77","author":"Naser","year":"2023","journal-title":"Med Arch"},{"issue":"11","key":"10.1016\/j.jacc.2025.03.544_bib86","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jacc.2025.03.544_bib87","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"issue":"9049","key":"10.1016\/j.jacc.2025.03.544_bib88","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(97)80008-6","article-title":"Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jacc.2025.03.544_bib89","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jacc.2025.03.544_bib90","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1161\/01.CIR.96.7.2197","article-title":"Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS)","volume":"96","author":"Lechat","year":"1997","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacc.2025.03.544_bib91","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacc.2025.03.544_bib92","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jacc.2025.03.544_bib93","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","article-title":"Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the EMPIRE HF randomized clinical trial","volume":"6","author":"Omar","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.jacc.2025.03.544_bib94","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/ejhf.2884","article-title":"Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: the DAPA-MODA study","volume":"25","author":"Pascual-Figal","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"21","key":"10.1016\/j.jacc.2025.03.544_bib95","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"issue":"10062","key":"10.1016\/j.jacc.2025.03.544_bib96","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","article-title":"Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial","volume":"388","author":"Teerlink","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jacc.2025.03.544_bib97","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ejhf.2836","article-title":"Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: the VICTORIA echocardiographic substudy","volume":"25","author":"Pieske","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"48","key":"10.1016\/j.jacc.2025.03.544_bib98","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1093\/eurheartj\/ehab411","article-title":"The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial","volume":"42","author":"Martens","year":"2021","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacc.2025.03.544_bib99","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1161\/CIRCHEARTFAILURE.114.001626","article-title":"Left ventricular reverse remodeling with biventricular versus right ventricular pacing in patients with atrioventricular block and heart failure in the BLOCK HF Trial","volume":"8","author":"St John Sutton","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.544_bib100","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10840-011-9584-y","article-title":"Cardiac resynchronization therapy in patients with mild heart failure: a systematic review and meta-analysis","volume":"32","author":"Santangeli","year":"2011","journal-title":"J Interv Card Electrophysiol"},{"issue":"6","key":"10.1016\/j.jacc.2025.03.544_bib101","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/pace.14661","article-title":"Reverse of left ventricular remodeling in heart failure patients with left bundle branch area pacing: systematic review and meta-analysis","volume":"46","author":"Siranart","year":"2023","journal-title":"Pacing Clin Electrophysiol"},{"issue":"12","key":"10.1016\/j.jacc.2025.03.544_bib102","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.03.544_bib103","doi-asserted-by":"crossref","unstructured":"Pabon MA, Vardeny O, Vaduganathan M, et al. Finerenone in heart failure with improved ejection fraction: the FINEARTS-HF trial. JAMA Cardiol. Published online May 21, 2025. https:\/\/doi.org\/10.1001\/jamacardio.2025.1101","DOI":"10.1001\/jamacardio.2025.1101"},{"issue":"9","key":"10.1016\/j.jacc.2025.03.544_bib104","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/ejhf.3001","article-title":"Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial","volume":"25","author":"Pabon","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10.1016\/j.jacc.2025.03.544_bib105","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/s41591-022-02102-9","article-title":"Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial","volume":"28","author":"Vardeny","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.jacc.2025.03.544_bib106","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jchf.2024.03.011","article-title":"Sex differences in heart failure with improved ejection fraction: the DELIVER trial","volume":"12","author":"Pab\u00f3n","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"10166","key":"10.1016\/j.jacc.2025.03.544_bib107","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jacc.2025.03.544_bib108","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/0735-1097(93)90578-O","article-title":"Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril","volume":"22","author":"Pflugfelder","year":"1993","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.jacc.2025.03.544_bib109","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.123.065748","article-title":"Blinded withdrawal of long-term randomized treatment with empagliflozin or placebo in patients with heart failure","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.jacc.2025.03.544_bib110","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1161\/CIRCULATIONAHA.110.976076","article-title":"Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry","volume":"122","author":"Poole","year":"2010","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.jacc.2025.03.544_bib111","doi-asserted-by":"crossref","first-page":"7752","DOI":"10.3390\/jcm12247752","article-title":"Cardiac magnetic resonance as risk stratification tool in non-ischemic dilated cardiomyopathy referred for implantable cardioverter defibrillator therapy\u2014state of art and perspectives","volume":"12","author":"Argentiero","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacc.2025.03.544_bib112","article-title":"Outcomes of spironolactone withdrawal in dilated cardiomyopathy with improved ejection fraction","volume":"8","author":"Chen","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.jacc.2025.03.544_bib113","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cardfail.2021.02.006","article-title":"Primary prevention implantable cardioverter-defibrillator therapy in heart failure with recovered ejection fraction","volume":"27","author":"Baman","year":"2021","journal-title":"J Card Fail"},{"issue":"5-6","key":"10.1016\/j.jacc.2025.03.544_bib114","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1159\/000526986","article-title":"Prediction of left ventricular reverse remodelling: a mini review on clinical aspects","volume":"147","author":"Chud\u00fd","year":"2022","journal-title":"Cardiology"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725062461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725062461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T01:04:07Z","timestamp":1782263047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725062461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":114,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0735109725062461"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.03.544","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heart Failure With Improved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.03.544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}